Novo Nordisk last week revealed that its oral GLP-1 drug failed to delay progression of Alzheimer's, deflating hopes that GLP-1s can treat neurodegenerative indications.
Why it matters: The setback blunts a potential value proposition behind pharma M&A in the short term, but industry experts remain hopeful.
